Company Announcements

Sareum Holdings PLC

("Sareum" or the "Company")

Notice of AGM, Annual Report and Accounts

Cambridge, UK, 24 November 2022 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces that the Company's Annual General Meeting ("AGM") will be held at 10.00 a.m. on 16 December 2022 at the offices of Peel Hunt LLP, 7th Floor, 100 Liverpool St, London EC2M 2AT.

The AGM will also be webcast via the Investor Meet Company ("IMC") platform. Shareholders who wish to follow the meeting via the IMC platform should register with IMC at www.investormeetcompany.com/sareum-holdings-plc/register-investor.

Shareholders are invited to listen to the meeting via the IMC platform and they will be able to raise questions with the Chairman, Chief Executive Officer and Chief Scientific Officer in a Q&A session to be held immediately after the AGM.  Shareholders are reminded that this will not constitute attendance at the AGM and shareholders will not be able to vote on the day.

Shareholders intending to vote should do so via the shareholder portal at www.signalshares.com where details of the procedure are shown. Alternatively, shareholders may request a paper form of proxy from our registrars, Link Group.

The notice of AGM, along with a copy of the Company's annual report and accounts for the year ended 30 June 2022, will be posted today to those shareholders who requested a hard copy. A copy of both documents will also be available on the Company's website www.sareum.com.

- Ends -

For further information, please contact: 

About Sareum

Sareum Holdings (AIM:SAR) is a  biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases with an initial focus on psoriasis. Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com